Advanced search
Publication Cover
Cancer Investigation Volume 8, 1990 - Issue 3-4
Submit an article Journal homepage
73
Views
57
CrossRef citations to date
0
Altmetric
Original Article

Mechanisms of Action and Clinical Uses of Estramustine

Ralph Benson Center for Urological Treatment and Research, 2201 Murphy Avenue, Suite 115, Nashville, Tennessee, 37203
&
Beryl Hartley-Asp Center for Urological Treatment and Research, 2201 Murphy Avenue, Suite 115, Nashville, Tennessee, 37203
Pages 375-380 | Published online: 11 Jun 2009

Citations (57)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Willi Kreis. (1995) Current Chemotherapy and Future Directions in Research for the Treatment of Advanced Hormone-Refractory Prostate Cancer. Cancer Investigation 13:3, pages 296-312.
Read now

Articles from other publishers (56)

Hanxiao Yu, He Yang, Enxue Shi & Wenjun Tang. (2020) Development and Clinical Application of Phosphorus-Containing Drugs. Medicine in Drug Discovery 8, pages 100063.
Crossref
Iris Alejandra García, Cintia Garro, Elmer Fernandez & Gastón Soria. (2020) Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 821, pages 111693.
Crossref
Yu-Ning Wong, Judith Manola, Gary R. Hudes, Bruce J. Roth, Judd W. Moul, Andrea M. Barsevick, Richard M. Scher, Michael J. Volk, David J. Vaughn, Stephen D. Williams, Michael J. Fisch, David Cella, Michael A. Carducci & George Wilding. (2018) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clinical Genitourinary Cancer 16:2, pages e315-e322.
Crossref
Vikram Patial, Supriya Sharma & Ugir Hossain Sk. (2017) Dendrimer conjugated estramustine nanocrystalline ‘Dendot’: An effective inhibitor of DMBA-TPA induced papilloma formation in mouse. European Journal of Pharmaceutical Sciences 109, pages 316-323.
Crossref
Daniel P. Petrylak & Navid Hafez. 2016. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice 77 92 .
Yasutomo Nakai, Kazuo Nishimura, Masashi Nakayama, Motohide Uemura, Hitoshi Takayama, Norio Nonomura & Akira Tsujimura. (2013) Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. International Journal of Clinical Oncology 19:1, pages 165-172.
Crossref
Ugir Hossain Sk, Deobrat Dixit & Ellora Sen. (2013) Comparative study of microtubule inhibitors – Estramustine and natural podophyllotoxin conjugated PAMAM dendrimer on glioma cell proliferation. European Journal of Medicinal Chemistry 68, pages 47-57.
Crossref
M. Laramas, C. Costan, A. Tessier & D. Farneti. (2011) Cancer de prostate métastatique résistant à la castration : le point de vue de l’oncologue médical. Médecine Nucléaire 35:6, pages 378-383.
Crossref
S. Sewak, S. Kosmider, V. Ganju, A. Woollett, E. G. Yeow, B. Le, M. Henry, M. A. Debrincat & R. Bell. (2010) Phase II study of paclitaxel and vinorelbine (Pacl‐Vin) in hormone‐refractory metastatic prostate cancer: double tubulin targeting. Internal Medicine Journal 40:3, pages 201-208.
Crossref
Jean-Pascal MachielsFilomena MazzeoMarylene ClausseBertrand FilleulLuc MarcelisBrigitte HonhonLionel D’HondtCatherine DopchieVincent VerschaeveLionel DuckDidier VerhoevenPeter JoustenMarie-Alix BonnyAnne-Marie MoxhonBertrand TombalJoseph Kerger. (2008) Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology 26:32, pages 5261-5268.
Crossref
Renu Mohan & Dulal Panda. (2008) Kinetic Stabilization of Microtubule Dynamics by Estramustine Is Associated with Tubulin Acetylation, Spindle Abnormalities, and Mitotic Arrest. Cancer Research 68:15, pages 6181-6189.
Crossref
Ronald de Wit. (2006) New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer. European Urology Supplements 5:15, pages 817-823.
Crossref
Guru Sonpavde, Thomas E. Hutson & William R. Berry. (2006) Hormone refractory prostate cancer: Management and advances. Cancer Treatment Reviews 32:2, pages 90-100.
Crossref
G. Di Lorenzo & S. De Placido. (2018) Hormone Refractory Prostate Cancer (Hrpc): Present and Future Approaches of Therapy. International Journal of Immunopathology and Pharmacology 19:1, pages 205873920601900.
Crossref
Jason Lester & Emma Hudson. 2006. Challenges in Prostate Cancer. Challenges in Prostate Cancer 258 272 .
A. Heidenreich. (2005) Therapie des hormonrefraktären ProstatakarzinomsTherapy of hormone-refractory prostate cancer. Der Urologe 44:12, pages 1481-1495.
Crossref
A. Heidenreich & C. H. Ohlmann. (2005) Therapieoptionen des hormonrefraktären ProstatakarzinomsTreatment options for hormone-refractory prostate cancer. Der Urologe 44:11, pages 1303-1314.
Crossref
Jorge A. Garcia, Vivian Weinberg & Eric J. Small. (2005) Prior Estrogen Therapy as a Predictor of Response to Subsequent Estramustine-Based Chemotherapy in Patients with Androgen-Independent Prostate Cancer. Clinical Prostate Cancer 4:2, pages 113-117.
Crossref
Manish S. Bhandari, Daniel P. Petrylak & Maha Hussain. (2005) Clinical trials in metastatic prostate cancer – Has there been real progress in the past decade?. European Journal of Cancer 41:6, pages 941-953.
Crossref
Mohammad Reza Safarinejad. (2005) Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Urologic Oncology: Seminars and Original Investigations 23:2, pages 93-101.
Crossref
A. Heidenreich, J. Wolf & K. Miller. (2005) Aktuelle Optionen der taxanbasierten Chemotherapie des hormonrefrakt�ren ProstatakarzinomsCurrent chemotherapy treatment options for hormone-refractory prostate cancer. Der Onkologe 11:1, pages 96-104.
Crossref
A. Heidenreich & C. H. Ohlmann. 2005. Pharmakotherapie in der Urologie. Pharmakotherapie in der Urologie 95 105 .
A. S. Merseburger, A. G. Anastasiadis, A. Stenzl & M. A. Kuczyk. 2005. Pharmakotherapie in der Urologie. Pharmakotherapie in der Urologie 85 94 .
Ulka Vaishampayan, Joseph Fontana, Wei Du & Maha Hussain. (2004) Phase II Trial of Estramustine and Etoposide in Androgen-Sensitive Metastatic Prostate Carcinoma. American Journal of Clinical Oncology 27:6, pages 550-554.
Crossref
Daniel P. Petrylak, Catherine M. Tangen, Maha H.A. Hussain, Primo N. LaraJr.Jr., Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna Berry, Carol Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan & E. David Crawford. (2004) Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. New England Journal of Medicine 351:15, pages 1513-1520.
Crossref
W Albrecht, H Van Poppel, S Horenblas, G Mickisch, A Horwich, V Serretta, G Casetta, J M Maréchal, W G Jones, S Kalman & R Sylvester. (2004) Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. British Journal of Cancer 90:1, pages 100-105.
Crossref
Wolfgang Hiddemann, Heinz Huber & Claus R. BartramR. Simak & M. Marberger. 2004. Die Onkologie. Die Onkologie 1233 1266 .
Johannes Wolff & Jens AltweinJohannes Wolff & Jens Altwein. 2004. Prostatakarzinom. Prostatakarzinom 61 106 .
Peter E. Clark & Frank M. Torti. (2003) Prostate Cancer and Bone Metastases: Medical Treatment. Clinical Orthopaedics and Related Research 415, pages S148-S157.
Crossref
Giuseppe Di Lorenzo, Riccardo Autorino, Michele De Laurentiis, Roberto Bianco, Rossella Lauria, Antonio Giordano, Marco De Sio, Massimino D'Armiento, Angelo Raffaele Bianco & Sabino De Placido. (2018) Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. Tumori Journal 89:4, pages 349-360.
Crossref
G.F Samelis, D Skarlos, D Bafaloukos, P Kosmidis, A Anagnostopoulos, G Aravantinos & M.A Dimopoulos. (2003) The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology 61:6, pages 1211-1215.
Crossref
Donald Trump & Yiu-Keung Lau. (2003) Chemotherapy of prostate cancer: Present and future. Current Urology Reports 4:3, pages 229-232.
Crossref
Elizabeth C. Kent & Maha H.A. Hussain. (2003) The rationale for adjuvant chemotherapy for high-risk prostate cancer. Current Opinion in Urology 13:2, pages 123-131.
Crossref
Axel Heidenreich & Andres J Schrader. (2003) The Treatment of Hormone Refractory Prostate Cancer. EAU Update Series 1:1, pages 40-50.
Crossref
Sanjeev Sewak, Abraham Chachoua, Anne Hamilton, Samir Taneja, Janet Lee, Minerva Utate, Joan Sorich & Franco M. Muggia. (2003) A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. Anti-Cancer Drugs 14:1, pages 67-72.
Crossref
A. Heidenreich. 2003. Prostate Cancer. Prostate Cancer 249 267 .
Ulka Vaishampayan, Joseph Fontana, Wei Du & Maha Hussain. (2002) An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology 60:6, pages 1050-1054.
Crossref
Timothy Gilligan & Philip W Kantoff. (2002) Chemotherapy for prostate cancer. Urology 60:3, pages 94-100.
Crossref
Wallace Akerley, James Butera, Terek Wehbe, Richard Noto, Barry Stein, Howard Safran, Frank Cummings, Sundaresan Sambandam, John Maynard, Gregory Di Rienzo & Louis Leone. (2002) A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 94:6, pages 1654-1660.
Crossref
Michael Naughton & Joel Picus. (2002) Advanced Prostate Cancer. American Journal of Cancer 1:1, pages 13-22.
Crossref
K.M Nicholson, R.M Phillips, S.D Shnyder & M.C Bibby. (2002) In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine. European Journal of Cancer 38:1, pages 194-204.
Crossref
S. Machtens. 2002. Pharmakotherapie in der Urologie. Pharmakotherapie in der Urologie 97 103 .
Julie A. Kish, Raviender Bukkapatnam & Felipe Palazzo. (2017) The Treatment Challenge of Hormone-Refractory Prostate Cancer. Cancer Control 8:6, pages 487-495.
Crossref
Andrew Pecora, Frank Richter, Anna Pavlick, Vincent Lanteri, John Scheuch, Stuart Levy, Gene Rosenberg & Jack Vitenson. (2002) Treatment of Metastatic Hormone Refractory Prostate Cancer with Ketoconazole, Hydrocortisone, and Cyclophosphamide. The Prostate Journal 3:2, pages 71-75.
Crossref
William K Oh, Daniel J George, Kristin Hackmann, Judith Manola & Philip W Kantoff. (2001) Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 57:1, pages 122-126.
Crossref
Marvin Rubenstein & Patrick Guinan. (2001) A Review of Various Antisense Oligonucleotide Therapeutic Approaches for Prostate Cancer. The Prostate Journal 2:4, pages 179-188.
Crossref
William K. Oh. (2000) Chemotherapy for patients with advanced prostate carcinoma. Cancer 88:S12, pages 3015-3021.
Crossref
J Wang & J Waxman. (2000) Chemotherapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations 5:3, pages 93-96.
Crossref
K. Edman, L. Svensson, B. Eriksson & P.O. Gunnarsson. (2000) Determination of estramustine phosphate and its metabolites estromustine, estramustine, estrone and estradiol in human plasma by liquid chromatography with fluorescence detection and gas chromatography with nitrogen-phosphorus and mass spectrometric detection. Journal of Chromatography B: Biomedical Sciences and Applications 738:2, pages 267-279.
Crossref
David C. Smith. (1999) CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America 26:2, pages 323-331.
Crossref
WILLIAM K. OH & PHILIP W. KANTOFF. (1998) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. The Journal of Urology, pages 1220-1229.
Crossref
WILLIAM K. OH & PHILIP W. KANTOFF. (1998) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. The Journal of Urology 160:4, pages 1220-1229.
Crossref
Lori A. Attivissimo, James V. Fetten & Willi Kreis. (1996) Symptomatic Improvement Associated With Combined Estramustine and Vinblastine Chemotherapy for Metastatic Prostate Cancer. American Journal of Clinical Oncology 19:6, pages 581-583.
Crossref
Charles Mahler & Louis J. Denis. (2006) Hormone refractory disease. Seminars in Surgical Oncology 11:1, pages 77-83.
Crossref
Louis J. Denis & Charles Mahler. 1994. Prostate Cancer 2000. Prostate Cancer 2000 71 82 .
L Denis. (1993) Prostate cancer. Primary hormonal treatment. Cancer 71:S3, pages 1050-1058.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.